ClinicalTrials.gg
TerminatedNCT02743806Updated Nov 18, 2023Results posted

Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease

A Phase 4 interventional study of Vedolizumab in Colitis, Ulcerative and Crohn Disease, sponsored by Takeda. Terminated at 78 sites in 18 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Why this study was terminated
Early Completed - Alternative Source of Drug Available

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
331
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Enrollment
10th of 38
331 · median 110
Started
2016
with 2 others
Phase 4
15 of 38
2 open now
Registered
11th of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 10th largest by enrollment, is one of 3 that started in 2016, is one of 15 in phase 4, and was the 11th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to monitor ongoing safety in participants with ulcerative colitis (UC) and Crohn's disease (CD) and to provide access to vedolizumab for qualifying participants who, in the opinion of the investigator, continue to derive benefit from vedolizumab and for whom continued treatment with vedolizumab is desired because there is no other comparable product available or the participant may be expected to develop worsening of disease if they were to modify treatment.

Read the detailed description

The drug being used in this study is called vedolizumab, which is being used to treat people who have ulcerative colitis or Crohn's disease. This study will monitor ongoing safety in the people who take vedolizumab.

Participants who have successfully completed the participation in qualifying vedolizumab clinical studies will be enrolled and assigned to receive:

  • Vedolizumab 300 mg

All participants will receive an intravenous (IV) infusion once every 8 weeks until vedolizumab is available through commercial channels, including reimbursement, for the participant's clinical scenario, or until participant withdrawal, whichever comes first. (Per MM approval, dosing regimen may be modified) This multicenter trial will be conducted worldwide. Participants will make multiple visits to the clinic and a final visit at 18 weeks after receiving the last dose of study infusion of vedolizumab for a safety follow-up assessment.

03

Conditions studied

  • Colitis, Ulcerative
  • Crohn Disease

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Received vedolizumab (excluding comparator or placebo participants) during participation in a qualifying vedolizumab study.
  2. In the opinion of the investigator, the participant is continuing to derive benefit from vedolizumab and continued treatment with vedolizumab is desired because there is no other comparable product available or the participant may be expected to develop worsening of disease if they were to modify treatment.
  3. A male participant who is non-sterilized and sexually active with a female partner of agrees to use adequate from signing of throughout the duration of the study and for 18 weeks after last dose.
  4. A female participant of childbearing potential who is sexually active with a non-sterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 18 weeks after last dose.

Exclusion criteria

Exclusion Criteria:

  1. For the participant's particular clinical scenario, vedolizumab is currently available to the participant through commercial channels, including reimbursement.
  2. Has any clinical condition or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study or unable to comply with the dosing requirements or poses a risk to the participant being in the study.
  3. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 18 weeks after participating in this study; or intending to donate ova during such time period.
  4. If male, the participant intends to donate sperm during the course of this study or for 18 weeks thereafter.
  5. Has received a in the last 18 weeks or is in need of a live vaccine during the study or up to 18 weeks after the last study dose.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
331 participants (actual)

Study arms

  • Experimental
    Vedolizumab 300 mg

    Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) that maybe reduced to once every 4 weeks (Q4W) based on the investigator's judgment of participant's clinical status and acknowledged by the medical monitor for up to 6 years.

    Drug: Vedolizumab

Interventions

  • Vedolizumab IV infusion

    Also known as: MLN0002, Entyvio, Kynteles

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the study drug. A SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires participant hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect or is an important medical event. Percentages are rounded off to the nearest decimal point.

    Time frame: From first dose of study drug in this XAP study through 18 weeks after the last dose of study drug (up to 6.3 years)

  2. Percentage of Participants With Adverse Events of Special Interest (AESIs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the study drug. AESIs included serious infections (opportunistic infections, such as progressive multifocal leukoencephalopathy \[PML\]), malignancies, liver injury, infusion-related hypersensitivity reactions, and injection site reactions. Percentages are rounded off to the nearest decimal point.

    Time frame: From first dose of study drug in this XAP study through 18 weeks after the last dose of study drug (up to 6.3 years)

07

Results

Posted Nov 18, 2023

Participant flow

Participants took part in the study at 78 investigative sites in Australia, Bulgaria, the Czech Republic, Estonia, Hungary, India, Italy, Republic of Korea, Latvia, Malaysia, New Zealand, Poland, Romania, Russian Federation, Serbia, South Africa, Turkey, and Ukraine from 01 August 2016 to 03 January 2023.

Participant flow — Overall Study
MilestoneVedolizumab 300 mg
Started331
Completed150
Not completed181
Withdrew: Adverse event9
Withdrew: Lost to follow-up8
Withdrew: Voluntary withdrawal54
Withdrew: Study termination65
Withdrew: Pregnancy6
Withdrew: No longer clinically benefiting27
Withdrew: Reason not specified12

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the study drug. A SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires participant hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect or is an important medical event. Percentages are rounded off to the nearest decimal point.

Time frame:
From first dose of study drug in this XAP study through 18 weeks after the last dose of study drug (up to 6.3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
percentage of participantsVedolizumab 300 mg
AEs61.9
SAEs15.1
PrimaryPercentage of Participants With Adverse Events of Special Interest (AESIs)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the study drug. AESIs included serious infections (opportunistic infections, such as progressive multifocal leukoencephalopathy \[PML\]), malignancies, liver injury, infusion-related hypersensitivity reactions, and injection site reactions. Percentages are rounded off to the nearest decimal point.

Time frame:
From first dose of study drug in this XAP study through 18 weeks after the last dose of study drug (up to 6.3 years)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events of Special Interest (AESIs)
percentage of participantsVedolizumab 300 mg
Percentage of Participants With Adverse Events of Special Interest (AESIs)3.9

Adverse events

Collected over From first dose of study drug in this XAP study through 18 weeks after the last dose of study drug (up to 6.3 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vedolizumab 300 mg1/331 (0.3%)50/331 (15.1%)100/331 (30.2%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventVedolizumab 300 mg
Colitis ulcerativeGastrointestinal disorders4/142
Crohn's diseaseGastrointestinal disorders5/189
Joint dislocationInjury, poisoning and procedural complications2/331
Myocardial infarctionCardiac disorders2/331
OsteoarthritisMusculoskeletal and connective tissue disorders2/331
SubileusGastrointestinal disorders2/331
Abdominal abscessInfections and infestations1/331
Abdominal painGastrointestinal disorders1/331
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/331
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/331
Most frequent other events
Most frequent other events
EventVedolizumab 300 mg
Crohn's diseaseGastrointestinal disorders35/189
Colitis ulcerativeGastrointestinal disorders20/142
NasopharyngitisInfections and infestations22/331
HypertensionVascular disorders21/331
COVID-19Infections and infestations17/331

Baseline characteristics

Full Analysis Set (FAS) consisted of all participants enrolled in the XAP study, who received at least 1 dose of study drug (i.e., vedolizumab IV treatment), including the dose given at T0 (last vedolizumab dose in the qualifying study).

Age, Continuous
Age, Continuous(years)Vedolizumab 300 mg
Mean44.5 ± 12.29
Sex: Female, Male
Sex: Female, Male(Participants)Vedolizumab 300 mg
Female147
Male184
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vedolizumab 300 mg
American Indian or Alaska Native0
Asian36
Native Hawaiian or Other Pacific Islander0
Black or African American3
White292
More than one race0
Unknown or Not Reported0
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Vedolizumab 300 mg
Region of Enrollment
Region of Enrollment(Participants)Vedolizumab 300 mg
Australia13
Bulgaria4
Czech Republic115
Estonia4
Hungary46
India13
Italy5
Korea, Republic of21
Latvia1
Malaysia1
New Zealand6
Poland41
Romania3
Russian Federation35
Serbia1
Turkey5
Ukraine5
South Africa12
Weight
Weight(kilograms (kg))Vedolizumab 300 mg
Mean76.91 ± 16.988
Height
Height(centimeters (cm))Vedolizumab 300 mg
Mean171.4 ± 11.06
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per meter square (kg/m^2))Vedolizumab 300 mg
Mean26.16 ± 5.667
08

Study locations

78 sites
  • The Canberra Hospital
    Garran, Australian Capital Territory 2605, Australia
  • Western Hospital
    Footscray, Victoria 3011, Australia
  • Cabrini Medical Centre
    Malvern, Victoria 3144, Australia
  • Box Hill Hospital
    Box Hill, 3128, Australia
  • Royal Brisbane & Women's Hospital
    Herston, 4029, Australia
  • Fiona Stanley Hospital
    Murdoch, 6150, Australia
  • Multiprofile Hospital For Active Treatment Ruse
    Ruse, 7002, Bulgaria
  • City Clinic University Multiprofile Hospital for Active Treatment EOOD
    Sofia, 1784, Bulgaria
  • Karlovarska krajska nemocnice a.s.
    Karlovy Vary, Karlovarsk Kraj 360 66, Czechia
  • Hepato-Gastroenterologie HK, s. r. o.
    Hradec Kralove, 500 12, Czechia
  • Oblastni nemocnice Kladno, a.s.
    Kladno, 272 01, Czechia
  • Nemocnice Pardubickeho kraje, a.s. Pardubicka nemocnice
    Pardubice, 532 03, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Praha 10, 100 34, Czechia
  • Institut klinicke a experimentalni mediciny
    Praha 4, 140 21, Czechia
  • ISCARE I.V.F. a.s.
    Praha 7, 170 00, Czechia
  • Nemocnice Strakonice, a.s.
    Strakonice, 386 29, Czechia
  • Nemocnice Tabor, a.s.
    Tabor, 390 03, Czechia
  • Krajska zdravotni, a.s. Masarykova nemocnice v Usti nad Labem, o.z.
    Usti Nad Labem, 401 13, Czechia
  • West Tallinn Central Hospital
    Tallinn, 10617, Estonia
  • East Tallinn Central Hospital
    Tallinn, EE-10138, Estonia
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, Csongrad 6720, Hungary
  • Bekes Megyei Kozponti Korhaz
    Bekescsaba, 5600, Hungary
  • Peterfy Sandor utcai Korhaz-Rendelintezet es Baleseti Kozpont
    Budapest, 1076, Hungary
  • Semmelweis Egyetem
    Budapest, 1088, Hungary
  • Szent Janos Korhaz es Eszak-Budai Egyesitett Korhazak
    Budapest, 1125, Hungary
  • Szent Pantaleon Korhaz-Rendelointezet
    Dunaujvaros, 2400, Hungary
  • Bugat Pal Korhaz
    Gyongyos, 3200, Hungary
  • Bekes Megyei Kozponti Korhaz
    Gyula, 5700, Hungary
  • Somogy Megyei Kaposi Mor Oktato Korhaz
    Kaposvar, 7400, Hungary
  • Karolina Korhaz Rendelointezet
    Mosonmagyarovar, 9200, Hungary
  • Kanizsai Dorottya Korhaz
    Nagykanizsa, 8800, Hungary
  • Pecsi Tudomanyegyetem
    Pecs, 7624, Hungary
  • Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz
    Szekesfehervar, 8000, Hungary
  • Tolna Megyei Balassa Janos Korhaz
    Szekszard, 7100, Hungary
  • Owaisi Hospital and Research Centre
    Hyderabad, Andhra Pradesh 500058, India
  • All India Institute of Medical Sciences
    New Delhi, Delhi 110029, India
  • Lakeshore Hospital
    Kochi, Kerala 682304, India
  • KEM Hospital Research Centre
    Pune, Maharashtra 411011, India
  • VGM Hospital Institute of Gastroenterology
    Coimbatore, Tamil Nadu 641005, India
  • Policlinico San Donato
    San Donato Milanese, Milano 20097, Italy
  • Istituto Clinico Humanitas
    Rozzano, 20089, Italy
  • Yeungnam University Hospital
    Daegu, 705-703, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
  • Severance Hospital Yonsei University Health System - PPDS
    Seoul, 120-752, Korea, Republic of
  • Kyung Hee University Hospital
    Seoul, 130-702, Korea, Republic of
  • Samsung Medical Center - PPDS
    Seoul, 135-710, Korea, Republic of
  • Asan Medical Center - PPDS
    Seoul, 138-736, Korea, Republic of
  • Pauls Stradins Clinical University Hospital
    Riga, LV-1002, Latvia
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Christchurch Hospital
    Christchurch, Canterbury 8011, New Zealand
  • Waikato Hospital
    Hamilton, Waikato 3240, New Zealand
  • Shakespeare Specialist Group
    Auckland, 620, New Zealand
  • Ars Medica
    Wroclaw, Dolnoslaskie 53-333, Poland
  • SP ZOZ Szpital Uniwersytecki w Krakowie
    Krakow, Malopolskie 31-531, Poland
  • Wojewodzki Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie
    Krakow, Malopolskie 31-826, Poland
  • Centrum Medyczne sw. Lukasza
    Czestochowa, Slaskie 42-202, Poland
  • SPZOZ Wojewodzki Szpital Zespolony im J Sniadeckiego
    Bialystok, 15-950, Poland
  • 10 Wojskowy Szpital Kliniczny z Poliklinika
    Bydgoszcz, 85-681, Poland
  • Corpora-Med
    Gliwice, 44-122, Poland
  • Centrum Zdrowia Matki, Dziecka i Mlodziezy
    Warsaw, 00-632, Poland
  • Centralny Szpital Kliniczny MSW
    Warszawa, 02-507, Poland
  • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu
    Wroclaw, 50556, Poland
  • Fundeni Clinical Institute
    Bucharest, 22322, Romania
  • Colentina Clinical Hospital
    Bucuresti, 20125, Romania
  • City Clinical Hospital #24
    Moscow, 125005, Russian Federation
  • Nizhegorodskaya Regional Clinical Hospital n.a. Semashko
    Nizhniy Novgorod, 603126, Russian Federation
  • Russian Medical Military Academy n.a. S.M. Kirov
    Saint Petersburg, 191015, Russian Federation
  • Medical Company Hepatolog, LLC
    Samara, 443093, Russian Federation
  • Union Clinic, LLC
    St. Petersburg, 191119, Russian Federation
  • St.Petersburg Multi Field City Hospital #2
    St. Petersburg, 194354, Russian Federation
  • Military Medical Academy
    Belgrade, 11000, Serbia
  • CLINRESCO, ARWYP Medical Suites
    Johannesburg, Gauteng 1619, South Africa
  • St Augustines Medical Centre
    Durban, Kwazulu - Natal 4001, South Africa
  • Kingsbury Hospital
    Claremont, Western Cape 7708, South Africa
  • Universitas Hospital
    Bloemfontein, 9301, South Africa
  • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi
    Istanbul, 34890, Turkey
  • Medical Clinical Research Center of Medical Center LLC Health Clinic
    Vinnytsia, Vinnyts'ka Oblast 21029, Ukraine
  • Poltava Regional Clinical Hospital n.a. M.V. Skliphosovskyi
    Poltava, 36011, Ukraine
09

References and documents

Publications

  • Danese S, Subramaniam K, Van Zyl J, Adsul S, Lindner D, Roth J, Vermeire S. Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. Aliment Pharmacol Ther. 2021 Jan;53(2):265-272. doi: 10.1111/apt.16160. Epub 2020 Nov 18. PubMed 33210333 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Jan 2023, 77 months.

Results were first posted in Nov 2023, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2016
First posted
Apr 19, 2016
StartActual
Aug 1, 2016
Primary completionActual
Jan 3, 2023
CompletionActual
Jan 3, 2023
Results first posted
Nov 18, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02743806
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Apr 19, 2016
Start date
Aug 1, 2016
Primary completion
Jan 3, 2023
Completion
Jan 3, 2023
Results posted
Nov 18, 2023
Last update
Nov 18, 2023

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion